ResearcherUniversity of AntwerpActive in the last 2 years

Robin Colenbier

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6694-8919; OpenAlex author ID A5090898921. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 2

Nucleoside analogue labelling to study the cell cycle of pancreatic cancer xenografts in the chicken embryo model Co-author DOI 10.1101/2025.09.09.675135 ↗
Hyperthermia Enhances Efficacy of Chemotherapeutic Agents in Pancreatic Cancer Cell Lines. First author DOI 10.3390/biom12050651 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Johannes Bogers · 2 shared papers, 2022–2025 · strength 0.52
- Paper Nucleoside analogue labelling to study the cell cycle of pancreatic cancer xenografts in the chicken embryo model DOI 10.1101/2025.09.09.675135 ↗
- Paper Hyperthermia Enhances Efficacy of Chemotherapeutic Agents in Pancreatic Cancer Cell Lines. DOI 10.3390/biom12050651 ↗
Luigi Brancato · 1 shared paper, 2022 · strength 0.15
- Paper Hyperthermia Enhances Efficacy of Chemotherapeutic Agents in Pancreatic Cancer Cell Lines. DOI 10.3390/biom12050651 ↗
Costanza E. Maurici · 1 shared paper, 2022 · strength 0.15
- Paper Hyperthermia Enhances Efficacy of Chemotherapeutic Agents in Pancreatic Cancer Cell Lines. DOI 10.3390/biom12050651 ↗
Elisa Giovannetti · 1 shared paper, 2022 · strength 0.15
- Paper Hyperthermia Enhances Efficacy of Chemotherapeutic Agents in Pancreatic Cancer Cell Lines. DOI 10.3390/biom12050651 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.